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Abstract  Detecting  a  new  area  of  contrast-enhancement  at  MRI  after  irradiation  of  malignant
brain tumor  arises  the  problem  of  differential  diagnosis  between  tumor  recurrence  and  radi-
ation necrosis  induced  by  the  treatment.  The  challenge  for  imaging  is  to  distinguish  the  two
diagnoses given:  the  prognostic  and  therapeutic  issues.  Various  criteria  have  been  proposed  in
the literature  based  on  morphological,  functional  or  metabolic  MRI.  The  purpose  of  this  study
was to  perform  an  analysis  of  these  tools  to  identify  MRI  best  criteria  to  differentiate  radi-
ation necrosis  lesions  from  malignant  gliomas  and  brain  metastases  recurrence.  For  gliomas,
the morphology  of  the  contrast-enhancement  cannot  guide  the  diagnosis  and  the  use  of  per-
fusion techniques  and  spectroscopy  (multivoxels  if  possible)  are  necessary.  In  the  follow-up  of
metastasis, a  transient  increase  and  moderate  lesion  volume  is  possible  with  a  good  prognosis.
Morphological  characteristics  (volume  ratio  T2/T1Gd)  and  perfusion  analysis  provide  valuable
tools for  approaching  the  diagnosis  of  radionecrosis.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Malignant  glial  tumors  and  metastases  currently  account  for  more  than  half  of  brain  tumors
(20  and  33%  respectively)  [1,2]  and  are  increasing  in  incidence.  Radiotherapy  (RT)  is  an
important  component  of  the  treatment  options  for  these  tumors  whether  used  alone  or
postoperatively.  Conventional  RT  is  given  for  glial  tumors  whereas  the  choice  of  type  of
irradiation  (whole  brain  or  stereotactic  for  cerebral  metastases)  depends  on  the  number
of  lesions  (stereotaxis  is  possible  when  there  are  no  more  than  3  to  5  secondary  lesions),
and  on  their  size.
∗ Corresponding author.
E-mail address: cottier@med.univ-tours.fr (J.-P. Cottier).
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This  radiotherapy,  which  has  been  shown  to  be  effec-
ive  (radiology  control  of  metastases  in  90%  of  cases  with
tereotactic  RT  and  a  signiﬁcant  improvement  of  survival
f  patients  receiving  radiochemotherapy  with  temozolo-
ide  (Temodal®)  following  excision  surgery  for  high-grade
liomas)  although  may  cause  severe  symptomatic  necrotic
nd  inﬂammatory  effects  and/or  effects  responsible  for
orrying  appearances.  The  irradiation  related  inﬂammatory
nd  necrotic  effect  is  then  responsible  for  contrast-
nhancement,  edema  and  a  space-occupying  lesion,  which
s  very  difﬁcult  to  distinguish  from  recurrence  or  continued
ctive  disease.
The  incidence  of  pronounced  radio-induced  lesions  has
een  estimated  depending  on  the  series  as  between  3  and
4%  [3,4]  for  glioblastomas  and  approximately  25%  for  irra-
iated  metastases  [5].  This  ﬁgure,  however,  is  rising  because
f  successive  irradiation  achieved  by  the  use  of  stereotac-
ic  RT  and  is  underestimated  (it  is  seen  concomitantly  with
ecurrences  and  is  involved  in  the  pseudoprogression  seen
ith  temozolomide).
During  post-irradiation  follow-up,  the  development  (or
ncrease)  in  contrast-enhancement  or  an  increase  in  size  of
olume  of  the  initial  lesion  therefore  raises  the  question  of
hether  the  disease  has  progressed  despite  treatment,  or
hether  temporary  irradiation-induced  necrosis  has  devel-
ped.  The  difﬁcult  role  of  the  expert  radiological  assessment
s  to  attempt  to  make  this  differential  diagnosis  in  order
o  adapt  the  subsequent  treatment  plan  or  radiological
onitoring.  Several  studies  (with  conventional  imaging  and
articularly  functional  and  metabolic  imaging  techniques)
ave  attempted  to  propose  radiological  signs  or  values,
hich  are  in  favor  of  necrosis  or  tumor  recurrence,  although
heir  sensitivities  and  speciﬁcities  vary  and  are  occasionally
ontradictory.  There  is  at  present  no  consensus  about  these
adiological  appearances  [6,7].  In  addition,  the  results  of
hese  studies  are  difﬁcult  to  incorporate  into  everyday’s
ractice  because  of  variations  in  the  imaging  techniques
sed,  the  heterogeneous  populations  studied  (malignant
liomas  and  metastases)  and  types  of  irradiation  (whole
rain  RT,  hypo-  or  normofractionation  or  stereotactic  RT).
The  aim  of  this  report  is  to  analyze  the  current  mor-
hological,  functional  and  metabolic  imaging  tools  from  a
iterature  review  in  order  to  identify  the  best  criteria  to  dis-
inguish  radionecrosis  lesions  from  a  tumor  recurrence  after
he  treatment  of  malignant  gliomas  and  cerebral  metas-
ases.
erebral radionecrosis: general
nformation
athological anatomy
lthough  the  mechanism  of  radio-induced  lesions  is  not
ntirely  understood,  it  is  accepted  that  the  initial  damage
s  vascular,  and  it  is  followed  by  glial  and  neuronal  effects.
his  is  combined  with  changes  in  the  enzyme  system  and
mmunological  mechanisms.  These  lesions  are  seen  a  few
onths  to  a  few  years  after  radiotherapy  has  ﬁnished  and
re  generally  irreversible  and  progressive.
In  the  acute  phase,  vasodilatation  occurs  with  increased
apillary  permeability  resulting  in  vasogenic  edema  [3,8].
E
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hickening  of  the  vascular  walls  then  develops  through
yalinization,  ﬁbrinoid  necrosis  of  both  the  vascular  wall
nd  endoluminal  thrombi  leading  to  infarction  and  tis-
ue  necrosis  [9].  The  extension  and  conﬂuence  of  necrotic
ffects  produce  a  serpiginous  or  geographical  appearance  in
ecrotic  parenchyma  [3]. Analysis  of  tissue  from  radionecro-
is  lesions  has  shown  an  absence  of  tissue  plasminogen
ctivator  and  excess  plasminogen  urokinase  activator.  This
mbalance  may  contribute  to  the  secondary  cytotoxic
dema,  which  leads  to  tissue  necrosis.  Vascular  endothe-
ial  growth  factor  (VGEF)  has  also  recently  been  implicated
10]: perinecrotic  tissue  astrocytes  are  VEGF  positive,  con-
ributing  to  the  local  proliferation  of  endothelial  cells.
hronically,  vascular  architectural  changes,  which  may  pro-
uce  telangiectasiae,  may  occur.
Oligodendrocytes  are  extremely  radiation  sensitive  and
heir  destruction  results  in  the  demyelination  lesions  seen
round  the  necrotic  areas  [3,11]. The  parenchymal  lesions
ostly  affect  the  white  matter  (WM)  and  underlying  laminar
ayer  of  the  cortex,  whereas  the  superﬁcial  cortex  is  rela-
ively  spared  [12]. Immunologically,  a true  immune  reaction
s  believed  to  develop  against  the  host.  In  the  late  phase,
part  from  gliosis  and  parenchymal  atrophy,  cysts  and  dys-
rophic  calciﬁcations  may  develop.
It  should  be  noted  that  post-irradiation  lesions  are  always
resent  to  variable  degrees  in  histological  examinations  of
xcised  tissue  and  which  enhance  on  imaging  in  the  irradi-
ted  area  accounting  for  between  30  and  65%  of  the  tissue
emoved  in  recurrences  of  glioblastomas  [13,14].
isk factors
he  factors  predisposing  to  radionecrosis  following  conven-
ional  RT  are  the  total  irradiation  dose,  the  size  of  the
olume  irradiated  [15,16],  a  small  number  of  fractions  [4],
he  staggering  of  the  treatment  over  time,  a  combination
f  chemotherapy,  length  of  survival  and  patient  age  (young
atients)  at  the  time  of  the  irradiation.  The  most  important
isk  factor  is  the  total  irradiation  dose  received.  The  inci-
ence  of  radiation  necrosis  doubles  and  quadruples  when
he  doses  exceed  62  Gy  and  78  Gy  respectively.
In  stereotactic  RT,  the  speciﬁc  risk  factors  are  the  volume
rradiated  at  the  12  Gy  dose  (over  8  cc),  previous  irradiation
nd  male  sex  [17,18].
The  chemotherapies  which  promote  the  development  of
adio-induced  lesions  are  cisplatin  and  carboplatin,  doxoru-
icin,  methotrexate  and  temozolomide  [17,19].
ime to onset
he  average  time  between  irradiation  and  clinical  or  radio-
ogical  suspicion  of  radionecrosis  in  patients  who  have
eceived  a  total  brain  dose  of  >  50  Gy  is  one  year,  although
ases  have  been  reported  from  a  few  months  up  to  several
ears  after  treatment  [20].  RT  causes  the  lesions  described
n  the  literature  under  the  term  pseudoprogression  in  the
nitial  weeks  or  months  after  RT  for  a  high-grade  glioma
ombined  with  chemotherapy.arly radionecrosis and pseudoprogression
he  current  reference  treatment  protocol  for  glioblastomas
Stupp  et  al.  [21]) includes  optimal  excision  of  the  tumor
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few  months,  some  lesions  continue  to  enlarge  with  a  tran-
sient  increase  in  the  cytotoxic  edema,  some  lesions  remain
stable  before  regressing  and  others  regress  from  the  start
(Fig.  2).  Early  surgery  may  be  required  for  symptomaticRadionecrosis  of  malignant  glioma  and  cerebral  metastasis  
followed  by  conventional  focused  beam  radiotherapy  and
concomitant  chemotherapy  and  then  adjuvant  chemother-
apy  with  temozolomide.  A  large  increase  in  the  size  of
contrast-enhancement  is  seen  in  the  weeks  or  months  after
radiotherapy  ﬁnishes  as  a  result  of  this  treatment  and
mimics  actual  tumor  progression  [22].  This  phase,  during
which  appearances  exacerbate  (‘‘pseudoprogression’’),
is  reported  in  20  to  30%  of  cases  and  is  followed  by  a
secondary  improvement  or  stabilization  without  additional
treatment  [23].  Patients  with  methylation  of  the  gene  cod-
ing  for  a  repair  enzyme  for  chemotherapy-induced  lesions,
O-6-methylguanine-DNA-methyltransferase  (MGMT),  deve-
lop  this  reaction  more  commonly  [23].  The  reaction  is
subacute  and  asymptomatic  in  most  patients  (70%).  Its  fea-
tures  (increase  or  development  of  contrast-enhancement
occurring  early  and  falling  over  time)  are  also  seen  in  radio-
therapy  without  temozolomide  although  is  more  common
and  occurs  earlier  when  temozolomide  is  used  in  associa-
tion.  Effective  radiotherapy  is  believed  to  cause  a  breach
in  the  blood-brain  barrier  (BBB)  facilitating  the  passage  of
the  drug  and  resulting  in  an  increase  in  its  activity.  In  early
radionecrosis,  gliosis  combined  with  inﬂammatory  changes
are  also  described  in  tissues  in  the  absence  of  viable  tumor
cells.  Early  radionecrosis  may  therefore  be  a  variant  of
pseudoprogression  and  some  authors  have  proposed  that  the
concept  of  treatment-induced  necrosis  and  its  radiological
features  should  be  included  in  the  term  pseudoprogression
and  replace  the  former  term,  early  radionecrosis  [24].
Methods of making the ﬁnal diagnosis
The  ﬁnal  diagnosis  of  radionecrosis  may  be  made  from  histo-
logical  ﬁndings  or  from  clinical  and  radiological  follow-up:
• histological  ﬁndings  obtained  from  excision  of  a  symp-
tomatic  lesion  or  biopsy  (although  this  raises  the  problem
of  how  representative  the  fragment  is);
• clinical  and  radiological  outcome,  which  requires  obser-
vation  periods  depending  on  the  studies  of  between  4
and  9  months  [5,8].  Lesions  which  regress  or  remain  sta-
ble  on  follow-up  MRI  during  hisperiod  without  additional
oncology  treatment  are  deemed  to  be  post-irradiation
damage.  Those  which  increase  progressively  in  size,  often
with  concomitant  clinical  deterioration,  are  interpreted
as  recurrence  of  tumor.
Magnetic resonance imaging of
radionecrosis
Whilst  the  underlying  histological  changes  in  radionecrosis
are  consistent  in  both  situations,  MRI  ﬁndings  (morphologi-
cal,  functional  and  metabolic)  and  the  diagnostic  problems
these  arias  are  very  different  after  treatment  for  a  malig-
nant  glioma  or  metastasis.
After treatment of a malignant glioma
Conventional  imaging
The  classical  appearances  are  those  of  a  mass  which
enhances,  with  a  central  necrotic  area  (Fig.  1).  Contrast-
enhancement  reﬂects  breach  of  the  BBB  secondary  to  the
endothelial  irradiation-induced  damage.  The  lesions  usually
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ccur  at  the  site  of  the  maximum  irradiation  dose,  i.e.  in  the
mmediate  vicinity  of  the  tumor  site  and  around  the  exci-
ion  cavity.  These  are  predominantly  in  the  white  matter
hich  contains  perivascular  coagulative  necrosis.  The  white
atter  is  particularly  vulnerable  to  the  secondary  ischemic
onsequences  of  post-irradiation  vasculopathy  [25].  The
eep  white  matter  has  a  relatively  poor  blood  supply  from
he  long  spinal  arteries  and  has  no  collateral  arterial  supply.
he  white  matter  arcuate  ﬁbers  which  also  receive  cortical
rterial  supply  are  more  resistant  to  radionecrosis  and  are
herefore  usually  affected  later  in  the  disease  process.
The  type  of  contrast  uptake  varies  greatly.  Enhancement
ay  be  nodular,  linear  or  curvilinear  [4],  heterogeneous
nd  annular  producing  ‘‘cut-green  pepper’’  (Fig.  1),  ‘‘soap
ubbles’’  or  ‘‘gruyere’’  cheese  appearances  [3,26].  Blurred
lumed  boundaries  appear  to  suggest  radionecrosis  com-
ared  to  the  nodular  boundaries  with  clear  edges  in  tumor
ecurrence  [27].  If  the  cortex  is  affected,  contrast  uptake
ay  be  gyriform  [3].
Whilst  these  effects  are  predominantly  seen  in  the  initial
umor  sites,  single  or  multifocal  post-irradiation  contrast-
nhancement  may  also  be  present  remote  to  the  tumor.  This
as  found  several  centimeters  from  the  initial  site  in  14  of
umar  et  al.’s  [3]  series  of  26  cases  of  radionecrosis  affected
he  corpus  callosum  in  6  patients,  the  contralateral  hemi-
phere  in  8  patients,  the  subependymal  regions  in  8  patients
nd  the  posterior  fossa  in  5  patients.
Hypointensities  indicative  of  hemorrhagic  changes  are
ften  seen  on  T2-weighted  echogradient  images.  These  were
eported  in  53%  of  cases  of  radionecrosis  by  Chan  et  al.  using
he  conventional  T2*  sequence  [28]  and  in  80%  of  cases  of
adionecrosis  using  magnetic  susceptibility  imaging  by  Zeng
l  al  [29].
The  space-occupying  effect  is  typically  very  small  for
he  size  of  lesion  although  the  reactive  vasogenic  edema
hich  accompanies  it  can  however  be  extensive  and  cause
 signiﬁcant  space-occupying  effect.  The  immediate  change
n  contrast-enhancement  varies  depending  on  the  dynamic
athophysiological  process  in  radionecrosis  lesions.  In  cases
f  possible  radionecrosis,  overan  observation  period  over  aigure 1. Right temporal radionecrosis. Nodular contrast-
nhancement with irregular boundaries containing ﬁne internal
eticulation giving it a ‘‘cut-green pepper’’ appearance.
988  A.  Raimbault  et  al.
Figure 2. Changes inradionecrosis lesions. T1-weighted axial images after gadolinium (a-e) and T2 FLAIR (f-j). High-grade left medial
temporal glial lesion (a) treated by surgery (complete excision), then RT and temodal chemotherapy (b: repeat MRI 3 months after surgery).
Development of medial temporal contrast and mesencephalic contrast-enhancement associated with perilesional edema on the repeat MRIat
6 months (c,h). On the repeat MRI performed 3 months later (d,i), there is an increase in the necrotic appearances of the lesion with slight
r he c
h
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e
l
o
r
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eegression of the T2-weighted hyperintensity. Three months later t
as melted away (e,j).
ctive  expansile  lesions  to  reduce  the  space-occupying
ffect  and  provide  an  unequivocal  diagnosis.Overall,  the  morphological  features  of  radionecrosis
esions  are  very  similar  to  those  of  a  recurrent  tumor:  type
f  contrast-enhancement,  site  (both  in  the  tumor  site  and
emote)  and  possible  transient  deterioration  [3].  According
i
c
t
eontrast-enhancement has disappeared and the perilesional edema
o  Mullins  et  al.  [26],  some  combinations  of  contrast-
nhancement  remote  to  the  initial  tumor  site  argue  more
n  favor  of  tumor  recurrence:  involvement  of  the  corpus
allosum  associated  with  multiple  enhancement  sites,  and  of
he  corpus  callosum  associated  with  subependymal  contrast-
nhancement  (Fig.  3).
Radionecrosis  of  malignant  glioma  and  cerebral  metastasis  
Figure 3. Recurrence of glioblastoma. T1-weighted axial image
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This  can  provide  information  about  the  capillary  microcir-after gadolinium. Appearance of contrast-medium in the corpus
callosum and the walls of the postoperative cavity.
Diffusion-weighted  imaging
The  apparent  diffusion  coefﬁcient  values  (ADC)  proposed  to
distinguish  recurrence  from  radionecrosis  in  the  literature
are  contradictory  (Table  1).
Several  studies  have  shown  a  signiﬁcantly  lower  ADC
in  tumor  recurrence  compared  to  radionecrosis  [8,30].
Histologically,  tumor  recurrence  contains  areas  of  viable
tumor  cells  with  pleimorphic  nuclei  and  a  dense  network
of  cytoplasmic  processes,  whereas  radiation-induced  tissue
necrosis  is  paucicellular  with  increased  water  in  the  inter-
stitial  spaces.  According  to  Hein  et  al.  [30],  the  ADC  ratio
(rADC  or  mean  ADC  of  the  contrast-enhancing  area/mean
ADC  of  the  same  area  in  the  contralateral  hemisphere)  is
more  discriminatory  than  absolute  ADC  values,  with  a signif-
icantly  higher  rADC  in  radionecrosis  (rADC  =  1.82)  compared
to  tumor  recurrence  (rADC  =  1.43).  Asao  et  al.  [8]  assessed
mean  and  maximum  ADC  values  in  these  areas  of  heteroge-
neous  structure  enhancement.  All  three  values  were  lower
in  tumor  recurrences  although  no  signiﬁcant  difference  was
found  except  for  the  maximum  ADC  (1.68.  10−3 mm/s2 mean
compared  to  2.3  ×10−3 mm/s2 for  radionecrosis).
Unlike  previous  studies,  Sundgren  et  al.  [31]  found  sig-
niﬁcantly  higher  mean  ADC  values  in  the  recurrence  group
(1.27  ×  10−3 mm/s2)  than  in  the  radionecrosis  group  of
patients  (1.12  ×  10−3 mm/s2)  and  no  signiﬁcant  difference
was  found  between  the  two  groups  in  another  study  [32].
Whilst  a  low  ADC  is  often  seen  in  tumor  recurren-
ces  because  of  high  cellularity,  ADC  values  may  also  be
c
b
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Table  1  Diffusion  values  to  distinguish  radionecrosis  from  rec
MF  Number  of  patients  Radionecrosis  
Total RN  R
[30]  1.5  T  18  6  12  ADCr  =  1.82  +  0
[8]  1.5  T  20  12  8  ADC  max  =  2.3  
[38]  1.5  T  28  12  16  ADC  mean  =  1.
FA  ratio  =  0.89  
[57]  3  T  55  23  32  ADCmean  =  1.3
ADCr  =  1.69
MF: magnetic ﬁeld; RN: radionecrosis; R: recurrence.989
ncreased  by  microangiogenesis  or  necrotic  effects.  Con-
ersely,  ﬁbrotic  lesions  and  inﬂammatory  effects  involving
acrophage  and  polynuclear  cell  inﬂux  [8]  explain  why
he  ADC  is  low  in  radionecrosis.  Hemorrhagic  changes  with
emosiderin  deposition  can  also  lead  to  a  reduced  signal  by
 T2*  or  T2  dark-through  effect  [33].
It  is  also  useful  to  study  ADC  values  in  the  T2-weighted
yperintense  area  located  outside  of  the  contrast-
nhancement  (‘‘perilesional  edema’’).  The  mean  ADC  in
adionecrosis  is  not  signiﬁcantly  different  between  the
nhancing  area  and  the  neighboring  area,  whereas  in  tumor
ecurrences,  the  ADC  is  higher  outside  of  the  contrast-
nhancement  [30,34].
iffusion  tensor  imaging
he  anisotropic  fraction  (AF)  is  related  to  histological  ﬁnd-
ngs  such  as  cellularity,  vascularization  and  the  structural
rganization  of  ﬁbers.  A  relationship  is  seen  between  the
all  in  AF  values  and  aggression  of  glial  lesions  [35].  In
adionecrosis  the  ﬁbers  and  normal  cells  are  destroyed
esulting  in  a  reduced  AF  [36,37]. This  is  associated  with  an
ncrease  in  mean  diffusivity,  also  affecting  the  apparently
ormal  white  matter  adjacent  to  the  edema.  [38].
erfusion  imaging
he  vascular  lesions  in  radionecrosis  involve  a  combina-
ion  of  extensive  ﬁbrinoid  necrosis  and  dilatation  of  blood
essels.  Tumor  recurrences  are  characterized  by  vascular
roliferation  with  a  high  tumor  vascular  density.  Histo-
ogical  examination  has  shown  that  tumor  recurrences
isplay  signiﬁcantly  higher  levels  of  neoangiogenesis  than  in
adionecrosis  [39,40],  although  the  cerebral  blood  volume
n  tumor  recurrences  is  signiﬁcantly  lower  than  in  the  ini-
ial  glioblastoma  [12,40]. Different  ways  of  analyzing  tissue
erfusion  are  available:  analysis  of  the  ﬁrst-pass  gadolin-
um  curve  on  T2*-weighted  imaging,  studying  T1-weighted
nhancement  dynamics  and  analysis  of  arterial  spin  labeling
ASL).
nalysis of the ﬁrst-pass gadolinium curveulation  from  measurement  of  various  parameters:  cerebral
lood  volume,  amplitude  of  the  signal  deﬂection  peak  and
ercentage  signal  recovery.
urrence  of  a high-grade  glial  lesion.
Recurrence
.07  ADCr  =  1.43  +  0.11
+  0.73  10−3 mm/s2 ADC  max  =  1.68  +  0.73  10−3 mm/s2
12  10−3 mm/s2
+  0.15
ADC mean  =  1.27  10−3 mm/s2
FA  ratio  =  0.74  +  0.14
9  10−3 mm/s2 ADCmean  =  1.2  10−3 mm/s2
ADCr  =  1.42
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Because  of  neoangiogenesis  the  perfusion  curves  show
 high  relative  cerebral  blood  volume  (rCBV  or  the  ratio
etween  the  blood  volume  in  the  lesion  and  the  blood  vol-
me  in  the  apparently  healthy  region  of  interest  positioned
n  the  contralateral  white  matter)  in  tumors  compared  to
 low  rCBV  in  radionecrosis  (Table  2),  (Figs.  4  and  5).
he  situation,  however,  is  more  complex  because  of  tis-
ue  heterogeneity,  breach  of  the  blood-brain  barrier  and
he  presence  of  free  radical  damage  inside  and  around  the
umors  [14,41]  explaining  the  overlapping  perfusion  values.
The  pilot  study  by  Sugahara  et  al.  [40]  showed  an  rCBV
utoff  of  under  0.6  for  radionecrosis  and  over  2.6  for  tumor
ecurrence,  with  no  clear  diagnosis  between  these  two  val-
es.  More  recently,  Bobek-Billewics  et  al.  [32]  proposed
 maximum  lower  cutoff  for  CBV  of  1.5  for  radionecrosis
nd  over  1.7  for  tumor  recurrence  with  similar  radiation-
nduced  lesions  to  those  reported  by  Barajas  et  al.  [13]
mean  rCBV  <  1.57  for  radionecrosis,  >  2.38  for  recurrences).
Extravasation  of  contrast-medium  into  the  extracellular
xtravascular  compartment  because  of  breach  of  the  blood-
rain  barrier  produces  an  increase  in  the  T1-weighted  signal,
ontrasting  with  the  fall  in  signal  due  to  the  reduction  in  T2*
eading  to  a  fall  in  the  calculated  relative  CBV  [36]. In  order
o  avoid  errors  due  to  extravasation  of  contrast-medium  due
c
t
Table  2  Perfusion  values  from  the  ﬁrst-pass  technique  to  dist
lesion.
Reference MF  Population  studied  
No.  of  patients  RN  
[40]  1.5  T  20  10  
[42]  3  T  13  (40  plvts)  16  
[69]  1.5  T  57  17  
[32]  1.5  T  and  3  T  11  6 
MF: magnetic ﬁeld; RN: radionecrosis; R: recurrence.
igure 4. Radionecrosis: ﬁrst-pass gadolinium curve. Left temporal g
 months after starting RT. Development of a vast area of necrosis of t
rCBV = 0.9; PSR = 100; rHP = 0.72) suggest radionecrosis which is conﬁrmA.  Raimbault  et  al.
o  the  T1-weighted  effect,  Hu  et  al.  [42]  carried  out  a  per-
usion  study  after  two  injections  of  gadolinium  (6  min  and
 min  after  a  bolus  injection)  and  proposed  a  cutoff  of  0.71
o  distinguish  recurrence  from  radionecrosis,  with  a  sensi-
ivity  of  91.7%  and  speciﬁcity  of  100%.  The  fall  in  T1  signal  as
 result  of  the  earlier  injection,  however,  causes  an  increase
n  the  T2*  susceptibility  effect  leading  to  a  fall  in  baseline
ignal  intensity  and  therefore,  a  lower  estimated  percent-
ge  signal  recovery.  An  alternative  to  preliminary  injection
o  counter  the  contrast-medium  extravasation  effect  on  T1
nd  T2*  signals  is  to  optimize  the  echo  time  and  tilt  angle  for
he  perfusion  sequence  (an  echo  time  of  54  ms  to  maximize
agnetic  susceptibility  effects  and  angle  of  35◦ to  mini-
ize  the  T1  effect  at  1.5  T),  although  this  carries  risks  of
verestimating  the  rCBV  [43].  New  calculation  algorithms
or  hemodynamic  response  are  based  on  bayesien  theory
nd  are  now  being  proposed.  These  provide  a  better  assess-
ent  of  blood  volume  and  improve  reproducibility  [44,45].
inally,  some  authors  have  used  other  contrast  media  such
s  ferumoxytol  (iron  oxide  nanoparticles)  which  does  not
xtravasate  because  of  the  large  particle  size  (up  to  50  nm
ompared  to  the  1  nm  size  of  the  gadolinium  chelate)  [46].
In  the  study  reported  by  Barajas  et  al.  [13],  the  best
he  ﬁrst-pass  curve  parameter  to  distinguish  between  lesions
inguish  radionecrosis  from  recurrence  of  a  high-grade  glial
Radionecrosis  Recurrence
R
10  rCBV  <  0.6  rCBV  >  2.6
24  rCBV  <  0.71  rCBV  >  0.71
40  rpH  <  1.38
rPRS  >  87.3%
rCBV  mean  =  1.57
rCBV  max  =  4.63
rpH  >  1.38
rPRS  <  87.3%
rCBV  mean  =  2.38
rCBV  max  =  8.16
5  rCBV  max  <  1.5
rCBV  mean  <  1
rCBV  max  >  1.7
rCBV  mean  >  1.25
lioblastoma treated with RT and temodal. Repeat MRI performed
he lesion with new contrast-enhancement. The curve parameters
ed by the secondary regression of the contrast-enhancement.
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bFigure 5. Recurrence of glioblastoma: ﬁrst-pass gadolinium curve.
site for the glioblastoma. The curve parameters (rCBV = 0.9; PSR = 0
was  the  relative  amplitude  of  the  peak  (rPA:  relative  peak
amplitude  in  the  lesion/peak  amplitude  in  the  healthy  area)
(Figs.  4  and  5).  This  is  higher  in  recurrences,  with  a  cutoff
value  of  1.38  giving  a  sensitivity  of  89%  and  speciﬁcity  of  81%.
Another  assessment  parameter  is  the  relative  percentage
signal  recovery  (PSR),  which  is  signiﬁcantly  lower  in  tumor
recurrence:  the  upper  cutoff  is  87.3%  with  a  sensitivity  of
78%  and  speciﬁcity  of  76%.
When  contrast  uptake  occurring  in  the  initial  weeks  fol-
lowing  irradiation  occurs  and  pseudoprogression  is  being
considered,  perfusion  imaging  is  also  extremely  valuable.
Mangla  et  al.  [47]  found  a  mean  reduction  in  rCBV  of  41%
in  pseudoprogression  compared  to  a  12%  increase  in  true
tumor  progression  (sensitivity:  77%  speciﬁcity  86%).  In  the
study  by  Kong  et  al.  [48],  a  signiﬁcant  difference  was  found
between  mean  CBV  for  pseudoprogression  and  tumor  recur-
rence:  ratio  over  1.49  (sensitivity  of  81.5%  and  speciﬁcity
of  77.8%)  for  the  diagnosis  of  tumor  recurrence  and  the
rCBV  was  a  better  index  for  tumor  recurrence  if  the  non-
methylated  patient.
Finally,  the  two  technical  difﬁculties  of  perfusion  analysis
should  be  remembered:
• EPI echo  gradient  imaging  may  be  uninterpretable  post-
operatively  because  of  magnetic  susceptibility  artifacts
due  to  the  metallic  material  adjacent  to  the  operation
site  (materials  relating  to  the  ﬂap,  metal  dust  left  during
drilling);
• Differences  in  perfusion  values  are  seen  according  to  the
power  of  magnetic  ﬁeld  and  the  sequence  parameters
used:  overestimation  of  the  CBV  and  HP  and  underesti-
mation  of  the  PT  in  3T  imaging  compared  to  1.5T  imaging
[49].
Study of T1-weighted dynamic enhancement
This  technique  provides  a  direct  measurement  of  cerebral
blood  volumes  and  ﬂows  and  the  permeability  of  the  blood-
brain  barrier  (using  parameters  such  as  the  le  Ktrans).  It
provides  absolute  blood  volume  values  without  the  need
to  correct  for  the  pass  contrast  curve  if  the  barrier  is
breached  [50]  and  without  the  need  for  a  reference  region.
p
r
l
aarances of nodular contrast-enhancement above the initial surgical
rHP = 2.3) showed tumor neoangiogenesis.
n  T1-weighed  imaging,  it  is  also  less  sensitive  to  magnetic
usceptibility  artifacts.  In  a  pilot  study  (of  18  patients,  3
atients  with  radionecrosis),  Larsen  et  al.  [51]  showed  that
ll  lesions  which  regressed  had  a  CBV  of  ≤  1.7  ml/100  g  and
hat  all  lesions  which  had  progressed  or  were  histologically
ound  to  be  malignant  had  a  CBV  of  ≥  2.2  ml/100  g.
erfusion analysis by arterial spin labeling
ASL)
n  a  study  comparing  ASL  ﬁndings,  ﬁrst-pass  of  gadolinium
nd  PET  CT,  Ozsunar  et  al.  [52]  found  ASL  to  offer  better
iagnostic  sensitivity  (sensitivities  of  88,  86  and  81%)  and  a
roposed  1.3  as  the  cutoff  value  for  the  standardized  ASL
atio  to  distinguish  radionecrosis  from  recurrence.  ASL  pro-
ides  an  absolute  quantiﬁcation  of  cerebral  blood  ﬂow  (but
ot  CBV)  and  is  not  affected  by  capillary  leakage,  which
eads  to  an  underestimation  of  CBV  and  ﬂow  when  the  curves
re  analyzed  after  gadolinium  enhancement.
pectroscopy
tructural  tissue  degradation  after  radiotherapy  is  accom-
anied  by  an  early  change  in  metabolic  activity  before
he  development  of  neurocognitive  symptoms  and  visible
natomical  changes  on  conventional  imaging.  Changes  in
erebral  metabolites  particularly  involve  N  acetylaspartate
NAA)  which  is  considered  to  be  a  neuronal  marker,  con-
entrations  of  which  fall  because  of  cell  death  by  apoptosis
r  neuronal  dysfunction.  The  second  metabolite  which  is
ffected  by  irradiation  is  choline,  levels  of  which  correlate
ith  the  biosynthesis  of  cell  membranes  and  with  metabolic
urnover.  Creatinine  (Cr),  a  marker  of  energy  metabolism,
s  considered  to  be  relatively  stable  in  radiation  damage
lthough  this  is  debated  (particularly  because  of  concomi-
ant  hypoxic  effects)  [53].  Classically  a  small  rise  in  the
ho  peak  and  Cho/Cr  ratio  is  seen  in  tissue  areas  involved
y  radionecrosis  (Fig.  6a).  Radiation  lesions  may  also  dis-
lay  a large  peak  located  between  0.8  and  2.4  ppm  which
eﬂects  the  presence  of  cell  debris  containing  fatty-acids,
actate  and  amino-acids  [54].  The  peaks  found  between  2.37
nd  2.4  ppm  in  severe  post-radiation  lesions  are  due  to  the
992  A.  Raimbault  et  al.
Figure 6. Spectroscopy. a: temporal radionecrosis after whole brain irradiation (monovoxel spectroscopy, TE: 135 ms): Cho/NAA ratio
1.15, inverted lactate peak present. b: tumor recurrence (monovoxel spectroscopy, TE: 135 ms): Cho/NAA ratio 2.3.
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sresence  of  co-existent  lactate  because  of  anaerobic  glycol-
sis  of  pyruvate  (2.37  ppm)  or  succinate  (2.4  ppm)  as  is  seen
n  abscesses.  Whilst  tumor  recurrences  are  also  associated
ith  a  fall  in  NAA,  they  do  however  display  a  large  rise  in
he  Cho  peak  because  of  cellular  proliferation  (Fig.  6b).
The  most  widely  used  ratios  in  the  literature  are
ho/Cr  and  Cho/NAA  [55,57]  (Table  3).  Elias  et  al.  [58]
m
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Table  3  Spectroscopic  studies  for  the  differential  diagnosis  b
lesion.
MF  Spectroscopy  Population  studies  
No.  of  patients  
Kimura  et  al.,
2001
1.5T  Monovoxel  26  
Schlemmer
et  al.,  2001
1.5T  Monovoxel  50  (66  samples)  
Rock  et  al.,  2002
[59]
1.5T  Multivoxels  Total  =  27  (42  spect
Rock  et  al.,  2004  1.5T  Multivoxels  18  (65  spectros)  
Webright  et  al.,
2005  [60]
1.5T  Multivoxels  30  
Zeng  et  al.,  2006
[29]
3T  Multivoxels  55  
Zeng  et  al.,  2007
[57]
3T  Multivoxels  28  
Smith  et  al.,  2009
[56]
1.5T  Multivoxels  33  howed  that  non-standardized  ratios  (with  the  lesion
etabolites  used  as  the  denominator)  correlated  far  more
trongly  with  the  diagnosis  than  standardized  ratios  (the
etabolite  in  the  ‘‘normal’’  contralateral  hemisphere  used
s  the  denominator).  Cutoff  values  vary  depending  on
he  study  (from  0.7  to  2  for  Cho/Cr).  These  differ-
nces  are  probably  due  to  small  numbers,  heterogeneous
etween  radionecrosis  and  recurrence  of  a  high-grade  glial
References  Studies
RN  R
7  19  Cho/Cr  <  2.48  Cho/Cr  >  2.38
32  34  ItCho/ItCr  =  1.26
±  0.61
ItCho/INAA  =  1.29
±  1.17
ItCho/ItCr  =  2.30
±  1.2
ItCho/INAA  =  3.44
±  2.76
ros)  15  27  Cho/nCr  < 0.89
Cho/nCho  <  0.66
Lip-Lac/Cho  >
1.36
Lip-Lac/nCr  >  2.84
Lip-Lac/Cho  <
0.75
Cho/nCr  >  1.79
33  28  Cho/NAA  <  0.2
NAA/nCr  >  1.56
NAA/Cho  >  1.32
12  18  rCho/Cr  = 1.52
rCho/NAA  =  1.31
rmean
NAA/Cr  =  1.22
rCho/Cr  =  2.52
rCho/NAA  =  3.48
rmoy/NAA/
23  32  Cho/Cr  =  1.61
Cho/NAA  =  1.55
Lac/Cr  =  0.45
Lip/Cr  =  0.54
NAA/Cr  =  1.1
Cho/Cr  =  2.82
Cho/NAA  =  3.52
9  19  Cho/NAA  and
Cho/Cr  >  1.71
13  20  Cho/NAA  <  1.1  Cho/NAA  >  2.3
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ﬁRadionecrosis  of  malignant  glioma  and  cerebral  metastasis  
tumors  and  the  difference  in  techniques  used  (mono  or
multivoxel).
Spectroscopic  analysis  has  several  limitations:lesions
close  to  bone  [13]  are  difﬁcult  to  study  reliably  because  of
magnetic  susceptibility  artifacts.
Whilst  spectroscopy  is  reliable  to  distinguish  tissues  con-
taining  pure  radionecrosis  or  a  pure  recurrence,  it  is  often
difﬁcult  to  interpret  because  of  the  frequent  co-existence
of  radiation  lesions  and  tumor  recurrence  [59].  The  metabo-
lite  values  are  therefore  averaged  within  the  voxel  taking
account  of  false  negatives  for  tumor  recurrence.  In  addi-
tion,  monovoxel  studies  only  provide  a  partial  metabolic
investigation  enhancing  large  or  multifocal  areas.  Multivoxel
spectroscopy  can  therefore  show  tumor  proﬁles  in  areas
which  do  not  enhance  and  in  the  apparently  neighboring
white  matter  [60].
After treatment of a cerebral metastasis
Conventional  imaging
A  transient  increase  in  volume  of  over  20%  of  the  pre-
treatment  volume  is  seen  in  a  third  of  cases  after
stereotactic  RT  for  cerebral  metastases  [61].  This  increase
in  size  may  begin  from  6  weeks  after  radiotherapy  and
last  for  up  to  15  months  [61].  It  is  more  common  in  men
and  if  the  irradiated  volume  is  over  5  cm3 [62]. The  natu-
ral  history  of  these  changes  in  volume  varies  depending  on
whether  or  not  the  primary  tumor  is  radiosensitive:  metas-
tases  from  radiosensitive  tumors  (lung,  breasts  and  colon)
display  a  transient  increase  in  volume  (peaking  between
12  and  18  months  after  radiotherapy)  whereas  the  volumes
of  metastases  from  non-radiosensitive  tumors  remain  rel-
atively  stable.  The  great  majority  of  these  increases  in
volume  is  asymptomatic  and  only  requires  monitoring.
In  the  study  by  Patel  et  al.  [61],  this  transient  increase
in  size  carried  a  good  prognosis:  when  present,  patients
had  longer  median  survival  (>  18.4  months)  than  those  whose
lesions  remained  stable  or  reduced  in  size  (16.4  months).
This  may  be  due  to  the  immune  reaction  associated  with  the
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Figure 7. Active progression of a metastasis. T1-weighted axial image
a right frontal metastasis. Large increase in volume of the lesion (> 65%)993
nﬂammation  and  necrosis  seen  in  these  radiation  reactions,
s  strong  immune  responses  are  associated  with  increased
urvival  and  control  of  cancers  [63].
In  general,  the  transient  increase  in  volume  post-
adiation  is  modest:  an  increase  of  more  than  65%  compared
o  the  volume  of  the  ﬁrst  post-treatment  review  suggests  a
ecurrence  or  continued  tumor  activity  (sensitivity:  100%,
peciﬁcity  80%)  [64]  (Fig.  7).
Several  studies  have  compared  the  appearances  of
nhanced  T2-weighted  and  T1-weighted  lesions.  Dequesada
t  al.  [7]  compared  the  area  of  the  visible  nodule  on  T2-
eighted  spin  echo  images  (AT2)  to  the  area  visible  on  the
1-weighted  image  after  gadolinium  (AT1Gd).  An  AT2/AT1Gd
adio  of  0.3  or  less  suggested  radionecrosis  (4  of  the  5  cases
f  radionecrosis)  whereas  all  of  the  pure  tumor  recurren-
es  (7  cases)  had  a  ratio  of  over  0.6.  The  post-irradiation
nﬂammatory  inﬁltrate  displays  an  obvious  hyperintensity  on
2-weighted  imaging,  unlike  the  T2-weighted  hypointensity
hich  a  number  of  metastases  display.  It  should  be  noted,
owever,  that  most  of  the  investigations  are  currently  per-
ormed  using  T2  ﬂair  sequences  in  which  most  metastases
ppear  as  hyperintense,  therefore  limiting  the  value  of  this
atio.  In  addition,  these  results  were  not  conﬁrmed  in  the
ore  recent  study  conducted  by  Stockham  et  al.  [65]  (51
atients  with  histological  conﬁrmation,  including  13  cases
f  radionecrosis)  in  which  the  lesion  quotient  only  provided
 sensitivity  of  8%  (speciﬁcity  91%).
Another  more  qualitative  method  is  based  on  the  correla-
ion  between  the  boundaries  of  the  lesion  seen  on  enhanced
1-weighted  and  T2-weighted  imaging  [66].  Correlations
eﬂect  tumor  recurrence  and  non-correlations  (‘‘T1/T2  mis-
atch’’)  reﬂect  radionecrosis  (Fig.  8,  Fig.  9).  The  sensitivity
f  the  ‘‘T1/T2  mismatch’’  in  this  study  was  83%  with  a  speci-
city  of  91%.
The  amount  of  edema  present  on  T2-weighted  imaging
as  also  been  studied  with  calculation  of  the  T2-weighted
yperintensity  volume/T1  weighed  volume  after  enhance-
ent.  When  over  10,  this  had  a  positive  predictive  value  of
2%  for  radionecrosis  [67].
s after gadolinium 12 (a) and 15 months (b) after radiotherapy for
 representing active recurrence.
994  A.  Raimbault  et  al.
Figure 8. Analysis of the T2/T1Gd ratio: active progression of a metastasis. T1-weighted axial (a) and T2 ﬂair (b) images after gadolinium.
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The  morphological  appearances  of  contrast  uptake
irregular,  annular  or  nodular)  are  non-speciﬁc.  This  includes
he  ‘‘sliced  leak’’  appearance  described  by  Dequesada  et  al.
7]  as  being  suggestive  of  a  diagnosis  of  radionecrosis,
lthough  this  has  not  been  found  by  other  authors  [64].
erfusion  imaging
n  electron  microscopy,  the  ultrastructure  of  the  tumor
apillaries  of  cerebral  metastases  resembles  more  that  of
he  original  tumor  than  the  cerebral  tissue  capillaries.  These
umor  vessels  display  increased  tortuosity,  lack  of  maturity
nd  increased  permeability.  In  addition,  as  they  do  not  have
he  blood-brain  barrier  of  the  native  cerebral  capillaries,
hey  are  very  permeable  to  macromolecular  contrast  agents.
Analysis  of  perfusion  images  in  the  literature  has  been
ased  on  relative  cerebral  blood  volume  (rCBV),  the  rela-
ive  amplitude  of  the  peak  (rHP)  and  the  percentage  signal
ecovery  (PSR)  [64,68,69].  All  authors  have  found  a signif-
cant  increase  in  average  and  maximum  rCBV  in  the  group
igure 9. Analysis of the T2/T1Gd ratio: radionecrosis. T1 (a) and T2
esion boundaries seen on T1 with enhancement and in T2-weighted ima
n the T2-weighted series.ent and in T2 (no T1/T2 mismatch). Signiﬁcant perilesional edema
f  patients  with  metastatic  recurrence  (the  best  cutoff  val-
es  range  from  1.52  to  2.1  depending  on  the  studies  [64,68]
Fig.  10,  Fig.  11).  rCBV  values  of  <  1.35  were  only  seen  in
he  group  of  patients  with  irradiation  lesions  in  the  study
eported  by  Barajas  et  al.  [69].
The  large  overlap  of  CBV  values  may  be  explained  by:
tumor  heterogeneity;
inability  to  distinguish  the  rise  in  microvascular  density
from  metastatic  recurrences  from  post-radiation  changes
in  vascularization  which  involve  hyper-plastic  dilated
blood  vessels;
the  co-existence  of  radionecrosis  lesions  with  tumor
recurrence  (50%  radionecrotic  tissue  in  tissue  samples
from  metastatic  recurrence);
magnetic  susceptibility  artifacts  due  to  petechial  hemor-
rhage  caused  by  the  irradiation,  which  artiﬁcially  reduce
the  rCBV  of  a  recurrence.  Similarly,  in  metastases  of
melanoma,  melanin  may  as  an  artifactimpede  the  analysis
of  the  CBV.
 ﬂair (b) axial images after gadolinium. Poor correlation between
ges (T1/T2 mismatch). Relatively insigniﬁcant perilesional edema
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lFigure 10. Perfusion study using the ﬁrst-pass technique: radion
volume mapping (b), ﬁrst-pass curves (c). Parameters obtained from
The  ratio  of  peak  amplitudes  is  also  higher  in  tumor  recur-
rence,  although  these  values  are  no  more  discriminatory
than  the  CBV.
According  to  Barajas  et  al.  [69]  studying  the  PSR  better
separated  metastatic  recurrence  from  radionecrosis  lesions.
These  authors  proposed  a  PSR  cutoff  value  of  76.3%  sup-
porting  radionecrosis  lesions,  with  a  sensitivity  of  95.65%
and  a  speciﬁcity  of  100%.  Lower  PSR  values  which  indicate
microvascular  leakage  in  metastatic  recurrences  probably
reﬂect  the  increase  in  capillary  permeability  of  tumor  ves-
sels.
Spectroscopy
Huang  et  al.  [64]  assessed  spectroscopy  to  distinguish
metastatic  recurrence  from  radionecrosis.  A  choline  ratio
(rCho  =  Cho  lesion/Cho  contralateral  healthy  area)  of  over
1.2  suggested  a  tumor  recurrence  (with  a  sensitivity  of  33%
and  speciﬁcity  of  100%)  and  was  of  better  diagnostic  value
than  the  conventional  ratios  (Cho/Cr  and  Cho/NAA).
Chernov  et  al.  [70]  primarily  used  the  lipid/Cho  ratio  and
found  that  a  value  of  3  or  a  large  fall  in  all  of  the  peaks
suggested  radionecrosis,  whereas  a  lipid/Cho  ratio  of  under
3  combined  with  a  NAA/Cho  ratio  of  under  1  was  seen  in
tumor  recurrence  (sensitivity  of  50%  and  speciﬁcity  100%  in
this  study).
a
m
t
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Figure 11. Perfusion study using the ﬁrst-pass technique: active prog
(a), cerebral blood volume mapping (b), ﬁrst-pass curves (c), paramet
rPH = 1.75.sis. T1-weighted axial image after gadolinium (a), cerebral blood
 curve for the PSR lesion = 77%, rCBV = 1, rPH = 0.8.
The  main  criteria  for  differential  diagnosis  by  MR  are
ummarized  in  Table  4.
cintigraphy investigations
8F-ﬂuorodeoxyglucose  has  been  studied  in  PET  CT,  based  on
he  premise  that  the  uptake  of  tracer  is  increased  by  tumor
etabolism  and  reduced  in  radionecrosis.  In  this  case  the
iagnostic  sensitivity  of  scintigraphy  has  been  reported  to
e  75%,  with  a  speciﬁcity  of  80%  [71].  Interpretation  of  18F-
DG-PET  CT  is  hindered  by  the  large  physiological  cortical
etabolic  activity  and  false  positive  results  may  occur  with
bscesses  and  from  the  inﬂammation  caused  by  radionecro-
is.
Other  tracers  can  be  used  in  PET  CT  in  this  sit-
ation,  including  amino-acids  (methionine,  tyrosine  and
holine)  and  nucleosides  (ﬂuorothymidine).  These  tracers
re  involved  in  protein  synthesis  and  are  good  indicators  of
ells  in  the  proliferative  phase.  The  extent  of  their  uptake
orrelates  with  disease  activity  or  tumor  regrowth.  They  are
omplicated  to  use  when  bound  to  C11  as  this  has  a  half-
ife  of  20  min  limiting  its  use  to  centers  located  close  to cyclotron,  radiochemistry  laboratories  and  the  radiophar-
acy  required  for  their  production.  These  tracers  have  been
ested  and  shown  sensitivity  of  95—100%  and  a  speciﬁcity  of
0  to  100%  [72].
ression of a metastasis. T1-weighted axial image after gadolinium
ers obtained from the curve for the PSR lesion = 53%, rCBV = 2.6;
996  A.  Raimbault  et  al.
Table  4  Main  MRI  criteria  for  the  differential  diagnosis  between  radionecrosis  and  metastases.
MRI  Radionecrosis  Recurrence  Reference
Conventional
sequences
Nodule  area  T2/T1
gado+  <  0.3
T1—T2:  tissue
boundaries  comparable
edema
volume/lesion  >  10
Nodule  area  T2/T1
gado+  <  0.6
T1—T2  mismatch
Volume
edema/lesion  <  10
Increased  volume  >  65%
Dequesada  et  al.,  2008
Stockham  et  al.,  2012
Kano  et  al.,  2010
Leeman  et  al.,  2013
Huang  et  al.,  2008
Barajas  et  al.,  2009
Perfusion  imaging rCBV  <  1.54 PSR  <  76.3%
Spectroscopy  Lipids/Cho  >  3  or  very
low  peaks
rCBV  >  2
rCBV  >  2.1
lipids/Cho  <  3  and
NAA/Cho  <  1
Huang  et  al.,  2008
Mitsuya  et  al.,  2010
Chernov  et  al.,  2006
Huang  et  al.,  2008
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aThe  tracers  can  now  be  labeled  with  ﬂuorine  18,  as  in
8F-ﬂuoroethyltyrosine,  which  greatly  facilitates  their  use
nd  the  wider  use  of  this  technique  [73].
Other  nuclear  medicine  methods  such  as  thallium-201
PECT  are  also  used  and  offer  a  sensitivity  and  speciﬁcity
f  90%  [74].  These  scintigraphic  methods  are  particularly
seful  when  magnetic  susceptibility  artifacts  are  present  on
R,  preventing  interpretation  of  advanced  MR  techniques
75].
reatment of radionecrosis
t  present,  there  is  no  speciﬁc  medical  treatment  for
adionecrosis.  Corticosteroids  are  usually  started  in  order
o  reduce  the  edema  and  inﬂammatory  components  associ-
ted  with  the  radionecrosis,  and  hyperbaric  oxygen  therapy
as  been  proposed  as  both  a  curative  and  preventative
reatment  [76].  Bevacizumab  (Avastin®)  in  particularhas
een  shown  to  be  effective  in  reducing  radionecrosis
esions  because  of  its  anti-angiogenic  (anti-VEGF)  proper-
ies  [77—79].  It  also  has  an  antineoplastic  effect  which  may
e  of  use  if  radiological  progression  remains  uncertain  [80].
Radionecrosis  lesions  occasionally  need  to  be  excised  sur-
ically  because  of  a  symptomatic  space-occupying  lesion
s
i
b
(rCho  >  1.2
ffect  or  if  diagnostic  doubt  is  present  about  lesions  located
n  a  non-functional  area  [81].
onclusion
eveloping  or  increasing  MRI  contrast-enhancement  in  an
rradiated  tumor  site  raises  the  question  of  the  differen-
ial  diagnosis  between  tumor  recurrence  and  radionecrosis.
n  view  of  the  therapeutic  and  prognostic  challenges,  it
s  important  that  the  MRI  conclusion  can  point  towards
ne  of  these  diagnoses  from  the  beginning.  With  irradi-
ted  glial  lesions  the  morphology  of  contrast-enhancement
annot  guide  the  diagnosis  and  perfusion  and  spectroscopy
echniques  (if  possible  using  multivoxels)  are  required.
uring  the  follow-up  of  metastases,  a  transient  moder-
te  increase  in  lesion  volume  may  occur  and  carry  a  good
rognosis.  The  morphological  features  (volume,  T2/T1Gd
atio)  and  perfusion  features  can  guide  towards  the  diag-
osis.  The  different  factors  pointing  towards  the  most
ppropriate  diagnosis  of  radionecrosis  on  MRI  criteria  are
ummarized  in  Fig.  12. A  diagnostic,  clinical  and  radiolog-
cal  approach  is  proposed  when  the  differential  diagnosis
etween  radionecrosis  and  recurrence  remains  problematic
Fig.  13).
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Figure 12. Elements of response for radionecrosis. More relevant MRI criteria.Figure 13. Clinical and radiological approach for the differential diagnosis between radionecrosis and tumor recurrence.
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TAKE-HOME  MESSAGES
• There  is  currently  no  morphological  criterion  to
separate  with  certainty  radionecrosis  and  recurrent
glioblastoma.
• In  the  follow-up  of  radiosurgery  for  brain  metastasis,
a  transient  and  moderate  increase  of  the  lesion
volume  is  possible  with  a  good  prognosis,  but  an
important  volume  increase  is  a  sign  of  recurrence.
• Corresponding  limits  of  the  lesion  on  T2  and  T1
gadolinium  sequences  was  in  favor  of  a  metastatic
recurrence.
• It  is  essential  to  add  advanced  techniques  sequences
(perfusion,  spectroscopy,  diffusion)  in  the  MR
protocol  in  an  attempt  to  differentiate  radiation
injury  from  tumor  recurrence.
• These  advanced  techniques  can  be  difﬁcult  to
interpret  given  the  heterogeneity  of  radionecrosis
lesions  and  the  frequent  association  of  these  lesions
with  evolving  tumor  tissues.
• The perfusion  imaging  (CBV  and  percent  recovery  of
the  signal)  is  currently  the  most  reliable  MR  method
to  separate  radionecrosis  from  tumor  recurrence.
isclosure of interest
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